arrow
W

Waldemar Halota

Department of Infectious Diseases and Hepatology
H指数:24
被引数:3,956

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
2022-09-018
OAAI
HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study
2022-01-134
OA
Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
2021-07-2517
OAAI
Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
2021-05-1411
OAAI
Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study

肝硬化和肝功能失代偿史患者直接抗病毒药物的真实世界有效性和安全性: Epi-Ter2研究

2021-03-1818
PREAI
Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

在现实世界中,格列卡普雷韦/皮布伦他韦的8周治疗方案是否足以满足所有感染丙型肝炎病毒的患者?

2020-11-2311
PREAI
Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA
2020-06-2714
PREAI
Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection
2020-02-0724
OA
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously difficult to treat patients infected with hepatitis C virus genotype 1 and 4
2020-01-169
PREAI
Efficacy of 8-versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting

在现实环境中,符合8周治疗方案的慢性丙型肝炎患者中,ledipasvir/sofosbuvir治疗8周与12周的疗效

2019-07-113
OAAI
Comparative effectiveness of 8 versus 12 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naive patients infected with HCV genotype 1b with non-advanced hepatic fibrosis
2019-04-010
PREAI
Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases-EpiTer-2 database analysis
2019-04-010
PREAI
Low risk of HBV reactivation in a large European cohort of HBV/HCV coinfected patients treated with DAA
2019-04-011
PREAI
Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting
2019-04-012
PREAI
The efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
2018-11-162
OAAI
The efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir and ledipasvir/sofosbuvir is similar in patients who failed interferon-based treatment with first generation protease inhibitors
2018-04-010
PREAI
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial
2016-12-0142
PREAI
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
2016-09-0994
OAAI